Beyond classical benzodiazepines: Novel therapeutic potential of GABA A receptor subtypes

Nature Reviews Drug Discovery

Volumn 10, Issue 9, 2011, Pages 685-697

  Rudolph, Uwe ^a   Knoflach, Frédéric ^b  

^a MCLEAN HOSPITAL   (United States)

^b Pharma Research and Early Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ADINAZOLAM; ALPRAZOLAM; ANXIOLYTIC AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CHLORDIAZEPOXIDE; DIAZEPAM; DOV 273547; FG 8094; GABOXADOL; HZ 166; IMIDAZENIL; L 655708; MIDAZOLAM; MK 0343; MK 0777; MORPHINE; MRK 016; MRK 409; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NS 113934; NS 11394; OCINAPLON; RO 4938581; TP 003; TPA 023; TPA 023B; TPA 123; UNCLASSIFIED DRUG; ZOLPIDEM;

ALLOSTERISM; ANALGESIA; ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; BINDING SITE; CATARACT; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISORIENTATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG TOLERABILITY; GABAERGIC SYSTEM; GENERALIZED ANXIETY DISORDER; HALLUCINATION; HIPPOCAMPUS; HUMAN; HYPERALGESIA; HYPNOSIS; INFLAMMATION; INSOMNIA; LIVER TOXICITY; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE RELAXATION; NEPHROTOXICITY; NERVE CELL PLASTICITY; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SPASTICITY; STROKE; TRANQUILIZING ACTIVITY; VENTRAL TEGMENTUM;

ANALGESICS; ANIMALS; ANXIETY DISORDERS; BENZODIAZEPINES; DEPRESSIVE DISORDER; GABA MODULATORS; HUMANS; HYPNOTICS AND SEDATIVES; MUTATION; NOOTROPIC AGENTS; RECEPTORS, GABA-A; SCHIZOPHRENIA; SLEEP INITIATION AND MAINTENANCE DISORDERS; STROKE; SUBSTANCE-RELATED DISORDERS;

EID: 80052274158     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3502     Document Type: Review

References (109)

1. Froestl, W. A historical perspective on GABAergic drugs. Future Med. Chem. 3, 163-175 (2011).
2. Mohler, H. The rise of a new GABA pharmacology. Neuropharmacology 60, 1042-1049 (2011).
3. Zeilhofer, H. U., Mohler, H. & Di Lio, A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol. Sci. 30, 397-402 (2009).
4. Atack, J. R. GABAA receptor α2/α3 subtype-selective modulators as potential nonsedating anxiolytics. Curr. Top. Behav. Neurosci. 2, 331-360 (2010).
5. Mirza, N. R. & Munro, G. The role of GABAA receptor subtypes as analgesic targets. Drug News Perspect. 23, 351-360 (2010).
6. Vinkers, C. H., Mirza, N. R., Olivier, B. & Kahn, R. S. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Exp. Opin. Invest. Drugs 19, 1217-1233 (2010).
7. Tan, K. R., Rudolph, U. & Luscher, C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 34, 188-197 (2011).
8. Schoch, P. et al. Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature 314, 168-171 (1985). (Pubitemid 15137126)
9. Mohler, H. & Okada, T. Benzodiazepine receptor: demonstration in the central nervous system. Science 198, 849-851 (1977). (Pubitemid 8214700)
10. Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. & Petersen, E. N. Interaction of convulsive ligands with benzodiazepine receptors. Science 216, 1241-1243 (1982). (Pubitemid 12082135)
11. Rudolph, U. et al. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature 401, 796-800 (1999).
12. McKernan, R. M. et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nature Neurosci. 3, 587-592 (2000). (Pubitemid 30332078)
13. Low, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131-134 (2000).
14. Crestani, F. et al. Trace fear conditioning involves hippocampal α5 GABAA receptors. Proc. Natl Acad. Sci. USA 99, 8980-8985 (2002). (Pubitemid 34693669)
15. Crestani, F. et al. Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. 59, 442-445 (2001). (Pubitemid 32179921)
16. van Rijnsoever, C. et al. Requirement of α5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J. Neurosci. 24, 6785-6790 (2004). (Pubitemid 38993900)
17. Tan, K. R. et al. Neural bases for addictive properties of benzodiazepines. Nature 463, 769-774 (2010).
18. Olsen, R. W. & Sieghart, W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56, 141-148 (2009).
19. Ulrich, D. & Bettler, B. GABAB receptors: synaptic functions and mechanisms of diversity. Curr. Opin. Neurobiol. 17, 298-303 (2007). (Pubitemid 46880321)
20. Pritchett, D. B. & Seeburg, P. H. γ-aminobutyric acidA receptor α5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. 54, 1802-1804 (1990).
21. Crestani, F., Martin, J. R., Mohler, H. & Rudolph, U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol. 131, 1251-1254 (2000).
22. Tobler, I., Kopp, C., Deboer, T. & Rudolph, U. Diazepam-induced changes in sleep: role of the α1 GABAA receptor subtype. Proc. Natl Acad. Sci. USA 98, 6464-6469 (2001). (Pubitemid 32488260)
23. Chandra, D. et al. GABAA receptor α4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. Proc. Natl Acad. Sci. USA 103, 15230-15235 (2006). (Pubitemid 44583193)
24. Dias, R. et al. Evidence for a significant role of α3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci. 25, 10682-10688 (2005). (Pubitemid 41681916)
25. Fischer, B. D. et al. Contribution of GABAA receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology 215, 311-319 (2010).
26. Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R. & Dawson, G. R. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl Acad. Sci. USA 102, 915-920 (2005). (Pubitemid 40282765)
27. Scott-Stevens, P., Atack, J. R., Sohal, B. & Worboys, P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm. Drug Dispos. 26, 13-20 (2005). (Pubitemid 40201967)
28. Atack, J. R. et al. TPA023 [7-(1,1-dimethylethyl)6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluor ophenyl)1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2-and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 316, 410-422 (2006). (Pubitemid 41832621)
29. Facklam, M. et al. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J. Pharmacol. Exp. Ther. 261, 1113-1121 (1992).
30. Lippa, A. et al. Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator. Proc. Natl Acad. Sci. USA 102, 7380-7385 (2005). (Pubitemid 40696386)
31. Czobor, P., Skolnick, P., Beer, B. & Lippa, A. A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder. CNS Neurosci. Ther. 16, 63-75 (2010).
32. Atack, J. et al. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J. Psychopharmacol. 25, 314-328 (2011).
33. Atack, J. et al. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. J. Psychopharmacol. 25, 329-344 (2011).
34. Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R. & Wiesbeck, G. A. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int. Clin. Psychopharmacol. 22, 292-298 (2007). (Pubitemid 47237548)
35. Kan, C. C., Breteler, M. H., van der Ven, A. H., Timmermans, M. A. & Zitman, F. G. Assessment of benzodiazepine dependence in alcohol and drug dependent outpatients: a research report. Subst. Use Misuse 36, 1085-1109 (2001). (Pubitemid 32730115)
36. Luscher, C. & Ungless, M. A. The mechanistic classification of addictive drugs. PLoS Med. 3, e437 (2006).
37. Heikkinen, A. E., Moykkynen, T. P. & Korpi, E. R. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 34, 290-298 (2009).
38. Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D. & Dawson, G. R. Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at α1 and α2/3 subtypes. J. Pharmacol. Exp. Ther. 332, 4-16 (2010).
39. Enna, S. J. & McCarson, K. E. The role of GABA in the mediation and perception of pain. Adv. Pharmacol. 54, 1-27 (2006).
40. Harris, J. A. & Westbrook, R. F. Effects of benzodiazepine microinjection into the amygdala or periaqueductal gray on the expression of conditioned fear and hypoalgesia in rats. Behav. Neurosci. 109, 295-304 (1995).
41. Knabl, J. et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 451, 330-334 (2008).
42. Fritschy, J. M. & Mohler, H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359, 154-194 (1995).
43. Elman, I., Zubieta, J. K. & Borsook, D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. Arch. Gen. Psych. 68, 12-20 (2011).
44. Munro, G. et al. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl- ethyl)-benzoimidazol-1-yl]biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 327, 969-981 (2008).
45. Mirza, N. R. et al. NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl) benzoimidazol-1-yl]biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J. Pharmacol. Exp. Ther. 327, 954-968 (2008).
46. Di Lio, A. et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 60, 626-632 (2011).
47. Munro, G., Erichsen, H. E., Rae, M. G. & Mirza, N. R. A question of balance-positive versus negative allosteric modulation of GABAA recetpor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain. Neuropharmacology 61, 121-132 (2011).
48. Yee, B. K. et al. A schizophrenia-related sensorimotor deficit links α3-containing GABAA receptors to a dopamine hyperfunction. Proc. Natl Acad. Sci. USA 102, 17154-17159 (2005). (Pubitemid 41692699)
49. Hauser, J. et al. Hippocampal α5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol. Psychiatry 10, 201-207 (2005). (Pubitemid 40188514)
50. Lubow, R. E. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr. Bull. 31, 139-153 (2005). (Pubitemid 41214363)
51. Grace, A. A., Floresco, S. B., Goto, Y. & Lodge, D. J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 30, 220-227 (2007). (Pubitemid 46654234)
52. Lisman, J. E. et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234-242 (2008).
53. Guidotti, A. et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology 180, 191-205 (2005). (Pubitemid 40909664)
54. Costa, E. & Guidotti, A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. 17, 192-200 (1996). (Pubitemid 26186205)
55. Gill, K. M., Lodge, D. J., Cook, J. M., Aras, S., Grace, A. A. A novel α5 GABAAR-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 11 May 2011 (doi:10.1038/npp.2011.76).
56. Delini-Stula, A. & Berdah-Tordjman, D. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia-a study group report. J. Psychiatr. Res. 30, 239-250 (1996). (Pubitemid 26340786)
57. Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nature Rev. Neurosci. 6, 312-324 (2005). (Pubitemid 40469985)
58. Lewis, D. A. et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165, 1585-1593 (2008).
59. Buchanan, R. et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 69, 442-449 (2011).
60. Castner, S. A. et al. Reversal of ketamine-induced working memory impairments by the GABAAα2/3 agonist TPA023. Biol. Psychiatry 67, 998-1001 (2010).
61. Holtzheimer, P. E. & Mayberg, H. S. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 34, 1-9 (2011).
62. Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Rev. Neurosci. 7, 137-151 (2006). (Pubitemid 43151600)
63. Luscher, B., Shen, Q. & Sahir, N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 16, 383-406 (2011).
64. Amsterdam, J. D., Hornig-Rohan, M. & Maislin, G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J. Clin. Psychiatry 55, 394-400 (1994). (Pubitemid 24337996)
65. Petty, F., Trivedi, M. H., Fulton, M. & Rush, A. J. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol. Psychiatry 38, 578-591 (1995).
66. Crestani, F. et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci. 2, 833-839 (1999). (Pubitemid 30491177)
67. Earnheart, J. C. et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 27, 3845-3854 (2007). (Pubitemid 46557682)
68. Shen, Q. et al. γ-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol. Psychiatry 68, 512-520 (2010).
69. Vollenweider, I., Smith, K. S., Keist, R. & Rudolph, U. Antidepressant-like properties of α2-containing GABAA receptors. Behav. Brain Res. 217, 77-80 (2011).
70. Buffett-Jerrott, S. E. & Stewart, S. H. Cognitive and sedative effects of benzodiazepine use. Curr. Pharm. Des. 8, 45-58 (2002). (Pubitemid 34449902)
71. Arolfo, M. P. & Brioni, J. D. Diazepam impairs place learning in the Morris water maze. Behav. Neural Biol. 55, 131-136 (1991).
72. Seabrook, G. R., Easter, A., Dawson, G. R. & Bowery, B. J. Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands. Neuropharmacology 36, 823-830 (1997). (Pubitemid 27286736)
73. Fritschy, J. M., Benke, D., Johnson, D. K., Mohler, H. & Rudolph, U. GABAA-receptor α-subunit is an essential prerequisite for receptor formation in vivo. Neuroscience 81, 1043-1053 (1997). (Pubitemid 27421768)
74. Prenosil, G. A. et al. Specific subtypes of GABAA receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons. J. Neurophysiol. 96, 846-857 (2006). (Pubitemid 44155222)
75. Zarnowska, E. D., Keist, R., Rudolph, U. & Pearce, R. A. GABAA receptor α5 subunits contribute to GABAA, slow synaptic inhibition in mouse hippocampus. J. Neurophysiol. 101, 1179-1191 (2009).
76. Yee, B. K. et al. GABA receptors containing the α5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur. J. Neurosci. 20, 1928-1936 (2004). (Pubitemid 39471587)
77. Collinson, N. et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J. Neurosci. 22, 5572-5580 (2002). (Pubitemid 35386478)
78. Ballard, T. M. et al. RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors. Psychopharmacology 202, 207-223 (2009).
79. Casula, M. A. et al. Identification of amino acid residues responsible for the α5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABAA receptor. J. Neurochem. 77, 445-451 (2001).
80. Atack, J. R. et al. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors. Neuropharmacology 51, 1023-1029 (2006). (Pubitemid 44691810)
81. Nutt, D. J., Besson, M., Wilson, S. J., Dawson, G. R. & Lingford-Hughes, A. R. Blockade of alcohol's amnestic activity in humans by an α5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 53, 810-820 (2007). (Pubitemid 350123479)
82. Atack, J. Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA. Pharmacol. Ther. 125, 11-26 (2010).
83. Atack, J. R. et al. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1, 2,4-triazol-5-ylme thoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor α5 subtype-selective inverse agonist. J. Pharmacol. Exp. Ther. 331, 470-484 (2009).
84. Dorow, R., Horowski, R., Paschelke, G. & Amin, M. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 2, 98-99 (1983). (Pubitemid 13066574)
85. Prut, L. et al. A reduction in hippocampal GABAA receptor α5 subunits disrupts the memory for location of objects in mice. Genes Brain Behav. 9, 478-488 (2010).
86. Clarkson, A. N., Huang, B. S., Macisaac, S. E., Mody, I. & Carmichael, S. T. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 468, 305-309 (2010).
87. Olsen, R. W. & Sieghart, W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 60, 243-260 (2008).
88. Bormann, J. The 'ABC' of GABA receptors. Trends Pharmacol. Sci. 21, 16-19 (2000). (Pubitemid 30102186)
89. Mohler, H., Fritschy, J. M. & Rudolph, U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300, 2-8 (2002). (Pubitemid 34028501)
90. Benke, D. et al. Analysis of the presence and abundance of GABAA receptors containing two different types of α subunits in murine brain using point-mutated α subunits. J. Biol. Chem. 279, 43654-43660 (2004). (Pubitemid 39390668)
91. Minier, F. & Sigel, E. Positioning of the α-subunit isoforms confers a functional signature to γ-aminobutyric acid type A receptors. Proc. Natl Acad. Sci. USA 101, 7769-7774 (2004). (Pubitemid 38658104)
92. Rudolph, U. & Antkowiak, B. Molecular and neuronal substrates for general anaesthetics. Nature Rev. Neurosci. 5, 709-720 (2004). (Pubitemid 39150142)
93. Jurd, R. et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA receptor β3 subunit. FASEB J. 17, 250-252 (2003).
94. Liao, M. et al. β3-containing γ-aminobutyric acidA receptors are not major targets for the amnesic and immobilizing actions of isoflurane. Anesth. Analg. 101, 412-418 (2005). (Pubitemid 41045223)
95. Lambert, S., Arras, M., Vogt, K. E. & Rudolph, U. Isoflurane-induced surgical tolerance mediated only in part by β3-containing GABAA receptors. Eur. J. Pharmacol. 516, 23-27 (2005). (Pubitemid 40780114)
96. Macdonald, R. L., Kang, J. Q. & Gallagher, M. J. Mutations in GABAA receptor subunits associated with genetic epilepsies. J. Physiol. 588, 1861-1869 (2010).
97. Covault, J., Gelernter, J., Hesselbrock, V., Nellissery, M. & Kranzler, H. R. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B, 104-109 (2004). (Pubitemid 38989078)
98. Edenberg, H. J. et al. Variations in GABRA2, encoding the α2 subunit of the GABAA receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 74, 705-714 (2004). (Pubitemid 38420099)
99. Agrawal, A. et al. Association of GABRA2 with drug dependence in the collaborative study of the genetics of alcoholism sample. Behav. Genet. 36, 640-650 (2006). (Pubitemid 44188079)
100. Dick, D. M. et al. Association between GABRA1 and drinking behaviors in the collaborative study on the genetics of alcoholism sample. Alcohol Clin. Exp. Res. 30, 1101-1110 (2006). (Pubitemid 43892898)
101. Drgon, T., D'Addario, C. & Uhl, G. R. Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 854-860 (2006). (Pubitemid 44905438)
102. Porjesz, B. et al. Linkage and linkage disequilibrium mapping of ERP and EEG phenotypes. Biol. Psychol. 61, 229-248 (2002). (Pubitemid 35248155)
103. Craddock, N. et al. Strong genetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotype. Mol. Psychiatry 15, 146-153 (2010).
104. Petryshen, T. L. et al. Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Mol. Psychiatry 10, 1074-1088, 1057 (2005).
105. Squires, R. F. & Brastrup, C. Benzodiazepine receptors in rat brain. Nature 266, 732-734 (1977). (Pubitemid 8073805)
106. Pirker, S., Schwarzer, C., Wieselthaler, A., Sieghart, W. & Sperk, G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101, 815-850 (2000).
107. Fagiolini, M. et al. Specific GABAA circuits for visual cortical plasticity. Science 303, 1681-1683 (2004). (Pubitemid 38338328)
108. Sohal, V. S., Keist, R., Rudolph, U. & Huguenard, J. R. Dynamic GABAA receptor subtype-specific modulation of the synchrony and duration of thalamic oscillations. J. Neurosci. 23, 3649-3657 (2003). (Pubitemid 36958473)
109. Rudolph, U., Crestani, F. & Mφhler, H. GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22, 188-194 (2001). (Pubitemid 32244305)